期刊
CLINICA CHIMICA ACTA
卷 528, 期 -, 页码 34-43出版社
ELSEVIER
DOI: 10.1016/j.cca.2021.12.029
关键词
Anti-dsDNA autoantibody; Systemic lupus erythematosus; Farr-RIA; CLIFT
资金
- FWO-TBM grant [T003419N]
Antibodies to dsDNA are crucial for the diagnosis, monitoring, and classification of SLE. However, different techniques for detecting and quantifying these antibodies have varying performance characteristics, and a combination of methods is often necessary for accurate interpretation of results.
Antibodies to dsDNA are an important laboratory parameter for diagnosis, monitoring and classification of systemic lupus erythematosus (SLE). In clinical laboratories, several techniques are used to detect and quantify anti-dsDNA antibodies. Each technique has its advantages and disadvantages regarding sensitivity, specificity, avidity and assay procedure. Assays differ with respect to the antigen source (native versus synthetic versus molecular biological) used and the way the antigen is presented (e.g. in solution, covalently linked to a solid phase,...). Consequently, correlation between assays can be poor and standardization of anti-dsDNA antibody tests is challenging. We here provide an overview of the currently available anti-dsDNA tests frequently used in clinical laboratories [Crithidia luciliae immunofluorescence test (CLIFT), Enzyme linked immune sorbent assay (ELISA), fluoroenzyme immunoassay (FEIA), chemiluminisence immunoassay (CIA), multiplexed bead-based assays and Farr-RIA] and their performance characteristics. From this literature study, we concluded that performance characteristics differ between assays. Often, a combination of techniques is necessary for the best result interpretation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据